Posted by Michael Wonder on 18 Dec 2022
Click Therapeutics receives FDA breakthrough device designation for prescription digital therapeutic to treat episodic migraine
16 December 2022 - Click Therapeutics today announced that it has received breakthrough device designation from the US FDA for CT-132.
Click’s CT-132 prescription digital therapeutic is under development as an adjunctive preventive treatment for episodic migraine in patients aged 18 years and older.
